Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03636906
Registration number
NCT03636906
Ethics application status
Date submitted
16/08/2018
Date registered
17/08/2018
Date last updated
27/07/2022
Titles & IDs
Public title
Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV
Query!
Scientific title
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Infants
Query!
Secondary ID [1]
0
0
2018-000431-27
Query!
Secondary ID [2]
0
0
204894
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Respiratory Syncytial Virus Infections
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - RSV (GSK3389245A) lower dose formulation vaccine
Other interventions - RSV (GSK3389245A) higher dose formulation vaccine
Other interventions - GSK's multicomponent meningococcal B vaccine
Other interventions - Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine
Other interventions - GSK's pneumococcal polysaccharide conjugate vaccine
Other interventions - GSK's meningococcal group A, C, W-135 and Y conjugate vaccine
Treatment: Drugs - Placebo
Experimental: RSV1D Pooled Group - Subjects received the interventions as follows:
Either 1 dose of experimental RSV (GSK3389245A) lower dose formulation at Day 1, followed by 1 dose of Placebo at Day 31 and any one the following active comparators: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Day 61 and at the end of RSV season 1) or 3 doses of GSK's multicomponent meningococcal B vaccine or Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine or GSK's pneumococcal polysaccharide conjugate vaccine (administered at Days 61, 121 and at the end of RSV season 1).
Or 1 dose of experimental RSV (GSK3389245A) lower dose formulation at Day 1, followed by 1 dose of Placebo at Day 31.
Experimental: RSV2D Pooled Group - Subjects received the interventions as follows:
Either 2 doses of experimental RSV (GSK3389245A) higher dose formulation (administered at Day 1 and Day 31) and followed by any one the following active comparators: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Day 61 and at the end of RSV season 1) or 3 doses of GSK's multicomponent meningococcal B vaccine or Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine or GSK's pneumococcal polysaccharide conjugate vaccine (administered at Days 61, 121 and at the end of RSV season 1).
Or 2 doses of experimental RSV (GSK3389245A) higher dose formulation administered at Day 1 and Day 31.
Active Comparator: Comparator_Placebo Pooled Group - Subjects received either one of interventions schedules as follows:
3 doses of GSK's multicomponent meningococcal B vaccine (administered at Days 1, 61 and at the end of RSV season 1) and 2 doses of Placebo (administered at Days 31 and 121).
3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Days 1, 61 and at the end of RSV season 1) and 2 doses of Placebo (administered at Days 31 and 121).
3 doses of GSK's pneumococcal polysaccharide conjugate vaccine (administered at Days 31, 61 and at the end of RSV season 1) and 2 doses of Placebo (administered at Day 1 and Day 121).
2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Day 31 and at the end of RSV season 1) and 2 doses of Placebo (administered at Days 1 and 61) .
2 doses of Placebo alone (administered at Days 1 and 31).
Other interventions: RSV (GSK3389245A) lower dose formulation vaccine
1 dose of RSV (GSK3389245A) lower dose formulation vaccine administered intramuscularly at Day 1.
Other interventions: RSV (GSK3389245A) higher dose formulation vaccine
2 doses of RSV (GSK3389245A) higher dose formulation vaccine administered intramuscularly, at Day 1 and Day 31.
Other interventions: GSK's multicomponent meningococcal B vaccine
3 doses of GSK's multicomponent meningococcal B vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
Other interventions: Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine
3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
Other interventions: GSK's pneumococcal polysaccharide conjugate vaccine
3 doses of GSK's pneumococcal polysaccharide conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 31, Day 61 and end of RSV season 1, depending on the vaccination schedule.
Other interventions: GSK's meningococcal group A, C, W-135 and Y conjugate vaccine
2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61 and at the end of RSV season 1, or at Day 31 and end of RSV season 1, depending on the vaccination schedule.
Treatment: Drugs: Placebo
1 dose or 2 doses of Placebo administered intramuscularly at Day 31, or at Day 1 and Day 31, or at Day 1 and Day 61, or at Day 31 and Day 121, depending on the vaccination schedule.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Subjects With Any Solicited Local Adverse Events (AEs) During a 7-day Follow-up Period After the First Vaccination (Administered at Day 1)
Query!
Assessment method [1]
0
0
Assessed solicited local AEs are erythema, pain and swelling at injection site. Any = occurrence of the adverse event regardless of intensity grade. Any redness and swelling = adverse event reported with a surface diameter greater than 0 millimeters. Analysis of this outcome measure were reported for the RSV1D pooled, RSV2D pooled, active comparators pooled and placebo groups separately to compare the expected adverse events observed from routine pediatric vaccines (active comparators) with the investigational RSV vaccine. Placebo was not pooled with active comparators as no significant difference was expected in AEs when placebo was pooled with active comparators. As pre-specified in the protocol, the choice of active comparator or placebo was based on each participating country's standard of care.
Query!
Timepoint [1]
0
0
During a 7-day follow-up period after the first vaccination (administered at Day 1)
Query!
Primary outcome [2]
0
0
Number of Subjects With Any Solicited Local Adverse Events (AEs) During a 7-day Follow-up Period After the Second Vaccination (Administered at Day 31)
Query!
Assessment method [2]
0
0
Analysis of this outcome measure were reported for the RSV1D pooled, RSV2D pooled, active comparators pooled and placebo groups separately to compare the expected adverse events observed from routine pediatric vaccines (active comparators) with the investigational RSV vaccine. Placebo was not pooled with active comparators as no significant difference was expected in AEs when placebo was pooled with active comparators. As pre-specified in the protocol, the choice of active comparator or placebo was based on each participating country's standard of care.
Query!
Timepoint [2]
0
0
During a 7-day follow-up period after the second vaccination (administered at Day 31)
Query!
Primary outcome [3]
0
0
Number of Subjects With Any Solicited General AEs During a 7-day Follow-up Period After the First Vaccination (Administered at Day 1)
Query!
Assessment method [3]
0
0
Assessed solicited general adverse events are drowsiness, fever [defined as temperature equal to or above (>=) 38.degrees Celsius (C)/100.4 Fahrenheit (F) by any route], irritability/fussiness and loss of appetite. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. Analysis of this outcome measure were reported for the RSV1D pooled, RSV2D pooled, each of the active comparators and placebo groups separately as the study interest was to investigate solicited AEs during the follow-up period of RSV vaccine administration, compared to placebo and routine pediatric vaccines, especially comparing to the rates of Bexsero-related fever. As pre-specified in the protocol, the choice of active comparator or placebo was based on each participating country's standard of care.
Query!
Timepoint [3]
0
0
During a 7-day follow-up period after the first vaccination (administered at Day 1)
Query!
Primary outcome [4]
0
0
Number of Subjects With Any Solicited General AEs During a 7-day Follow-up Period After the Second Vaccination (Administered at Day 31)
Query!
Assessment method [4]
0
0
Analysis of this outcome measure were reported for the RSV1D pooled, RSV2D pooled, each of the active comparators and placebo groups separately as the study interest was to investigate solicited AEs during the follow-up period of RSV vaccine administration, compared to placebo and routine pediatric vaccines, especially comparing to the rates of Bexsero-related fever. As pre-specified in the protocol, the choice of active comparator or placebo was based on each participating country's standard of care.
Query!
Timepoint [4]
0
0
During a 7-day follow-up period after the second vaccination (administered at Day 31)
Query!
Primary outcome [5]
0
0
Number of Subjects With Any Unsolicited AEs
Query!
Assessment method [5]
0
0
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Unsolicited AEs are reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to study vaccination. Analysis of this outcome measure were reported for the RSV1D pooled, RSV2D pooled, and comparator_placebo pooled groups as data collection was based on different standard of care provided at participating countries rather than randomization to each of the individual groups. According to the pre-specified analysis plan, data collected for participant flow, baseline characteristics and adverse events reporting were not analyzed for the individual groups.
Query!
Timepoint [5]
0
0
During a 30-day follow-up period across the 2 vaccinations administered at Day 1 and Day 31
Query!
Primary outcome [6]
0
0
Number of Subjects With Any Serious Adverse Events (SAEs) From Day 1 up to Day 61
Query!
Assessment method [6]
0
0
Assessed serious adverse events (SAEs) include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity. Any = occurrence of SAE regardless of intensity grade or relation to study vaccination. Analysis of this outcome measure were reported for the RSV1D pooled, RSV2D pooled, and comparator_placebo pooled groups as data collection was based on different standard of care provided at participating countries rather than randomization to each of theindividual groups. According to the pre-specified analysis plan, data collected for participant flow, baseline characteristics and adverse events reporting were not analyzed for the individual groups.
Query!
Timepoint [6]
0
0
From Day 1 up to Day 61
Query!
Primary outcome [7]
0
0
Number of Subjects With Episode of Spontaneous or Excessive Bleeding (AE of Special Interest)
Query!
Assessment method [7]
0
0
Any episode of spontaneous or excessive bleeding if occurring after vaccination was to be fully investigated with a full range of hematological tests to identify the underlying cause and reported as an AE of special interest. Analysis of this outcome measure were reported for the RSV1D pooled, RSV2D pooled, and comparator_placebo pooled groups as data collection was based on different standard of care provided at participating countries rather than randomization to each of the individual groups. According to the pre-specified analysis plan, data collected for participant flow, baseline characteristics and adverse events reporting were not analyzed for the individual groups.
Query!
Timepoint [7]
0
0
During a 30-day follow-up period across the 2 vaccinations administered at Day 1 and Day 31
Query!
Secondary outcome [1]
0
0
Number of Subjects With Respiratory Tract Infection Associated With RSV Infection (RSV-RTI), Lower Respiratory Tract Infection Associated With RSV Infection (RSV-LRTI), Severe RSV-LRTI and Very Severe RSV-LRTI (According to Standardized Case Definitions)
Query!
Assessment method [1]
0
0
According to standardized case definitions,RSV-RTI is a subject having runny nose/blocked nose/ cough & confirmed RSV infection.RSV-LRTI is a subject having history of cough/ difficulty breathing[based on history reported by parents] & blood oxygen saturation (SpO2) lower than(<)95 percent (%)/ respiratory rate (RR) increase & confirmed RSV infection Severe RSV-LRTI-Cases meeting RSV-LRTI case definition & an SpO2<93 %/lower chest wall in-drawing. Very severe RSV-LRTI-Cases meeting RSV-LRTI case definition & an SpO2<90%/inability to feed/failure to respond/unconscious.Analysis of this outcome measure was reported for RSV1D pooled, RSV2D pooled & comparator_placebo pooled groups as data was collected based on different standard of care provided at participating countries rather than randomization to each of the groups.Per the pre-specified analysis plan,data collected for participant flow, baseline characteristics and adverse events reporting were not analyzed for the individual groups
Query!
Timepoint [1]
0
0
From first vaccination (Day 1) up to the end of the first RSV transmission season (up to 1 year)
Query!
Secondary outcome [2]
0
0
Number of Subjects With RSV-RTI, RSV-LRTI, Severe RSV-LRTI and Very Severe RSV-LRTI (According to Standardized Case Definitions)
Query!
Assessment method [2]
0
0
Analysis of this outcome measure were reported for the RSV1D pooled, RSV2D pooled, and comparator_placebo pooled groups as data collection was based on different standard of care provided at participating countries rather than randomization to each of the individual groups. According to the pre-specified analysis plan, data collected for participant flow, baseline characteristics and adverse events reporting were not analyzed for the individual groups.
Query!
Timepoint [2]
0
0
From first vaccination (Day 1) up to the end of the second RSV transmission season (up to 2 years)
Query!
Secondary outcome [3]
0
0
Number of Subjects With SAEs From First Vaccination (Day 1) up to the End of the Second RSV Transmission Season (up to 2 Years)
Query!
Assessment method [3]
0
0
Analysis of this outcome measure were reported for the RSV1D pooled, RSV2D pooled, and comparator_placebo pooled groups as data collection was based on different standard of care provided at participating countries rather than randomization to each of the 15 groups. According to the pre-specified analysis plan, data collected for participant flow, baseline characteristics and adverse events reporting were not analyzed for the individual groups.
Query!
Timepoint [3]
0
0
From first vaccination (Day 1) up to the end of the second RSV transmission season (up to 2 years)
Query!
Secondary outcome [4]
0
0
Number of Subjects With RSV-LRTI (AE of Special Interest) From First Vaccination (Day 1) up to the End of the First RSV Transmission Season (up to 1 Year)
Query!
Assessment method [4]
0
0
Subjects experiencing an LRTI associated with RSV infection were reported as AE of special interest. To identify RSV-LRTI for the purpose of AE of specific interest, the diagnosis was based on the investigators' clinical judgment taking into account the clinical history, the examination, relevant medical investigations and locally-available diagnostic test for RSV. Analysis of this outcome measure were reported for the RSV1D pooled, RSV2D pooled, and comparator_placebo pooled groups as data collection was based on different standard of care provided at participating countries rather than randomization to each of the individual groups. According to the pre-specified analysis plan, data collected for participant flow, baseline characteristics and adverse events reporting were not analyzed for the individual groups.
Query!
Timepoint [4]
0
0
From first vaccination (Day 1) up to the end of the first RSV transmission season (up to 1 year)
Query!
Secondary outcome [5]
0
0
Number of Subjects With RSV-LRTI (AE of Special Interest) From First Vaccination (Day 1) up to the End of the Second RSV Transmission Season (up to 2 Years)
Query!
Assessment method [5]
0
0
Analysis of this outcome measure were reported for the RSV1D pooled, RSV2D pooled, and comparator_placebo pooled groups as data collection was based on different standard of care provided at participating countries rather than randomization to each of the individual groups. According to the pre-specified analysis plan, data collected for participant flow, baseline characteristics and adverse events reporting were not analyzed for the individual groups.
Query!
Timepoint [5]
0
0
From first vaccination (Day 1) up to the end of the second RSV transmission season (up to 2 years)
Query!
Secondary outcome [6]
0
0
Number of RSV Infected Subjects With a Negative RSV Exposure Status (at Screening Based on In-stream Baseline Serological Testing) With Very Severe RSV-LRTI (According to Standardized Case Definition)
Query!
Assessment method [6]
0
0
Very severe RSV LRTI are cases meeting the case definition of RSV-LRTI AND a SpO2 <90%, OR inability to feed, OR failure to respond/unconscious. Analysis of this outcome measure were reported for the RSV1D pooled, RSV2D pooled, and comparator_placebo pooled groups as data collection was based on different standard of care provided at participating countries rather than randomization to each of the individual groups. According to the pre-specified analysis plan, data collected for participant flow, baseline characteristics and adverse events reporting were not analyzed for the individual groups.
Query!
Timepoint [6]
0
0
From first vaccination (Day 1) up to the end of the first RSV transmission season (up to 1 year)
Query!
Secondary outcome [7]
0
0
Anti-RSV-A Neutralizing Antibody Titers
Query!
Assessment method [7]
0
0
Humoral response to the investigational RSV vaccine was measured in terms of anti-RSV-A neutralizing antibody titers and expressed as geometric mean titers (GMTs) in Estimated Dilution 60 (ED60) titers. Analysis of this outcome measure were reported for the RSV1D pooled, RSV2D pooled, and comparator_placebo pooled groups as data collection was based on different standard of care provided at participating countries rather than randomization to each of the individual groups. According to the pre-specified analysis plan, data collected for participant flow, baseline characteristics and adverse events reporting were not analyzed for the individual groups.
Query!
Timepoint [7]
0
0
At pre-vaccination (Screening), Day 31, Day 61 and at the end of the first RSV transmission season (EOS1) (up to 1 year)
Query!
Secondary outcome [8]
0
0
Anti-RSV-F Antibody Concentrations
Query!
Assessment method [8]
0
0
Humoral response to the investigational RSV vaccine was measured in terms of anti-RSV-F antibody concentrations and expressed as geometric mean concentrations (GMCs) in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EU/mL). Analysis of this outcome measure was reported for the RSV1D pooled, RSV2D pooled, and comparator_placebo pooled groups as data collection was based on different standard of care provided at participating countries rather than randomization to each of the individual groups. According to the pre-specified analysis plan, data collected for participant flow, baseline characteristics and adverse events reporting were not analyzed for the individual groups.
Query!
Timepoint [8]
0
0
At pre-vaccination (Screening), Day 31, Day 61 and at the end of the first RSV transmission season (EOS1) (up to 1 year)
Query!
Eligibility
Key inclusion criteria
- Subjects' parent(s)/Legally Acceptable Representative [LAR(s)] who, in the opinion of
the investigator, can and will comply with the requirements of the protocol
- Written informed consent obtained from the parent(s)/LAR(s) of the subject prior to
performing any study specific procedure.
- A male or female between and including 6 and 7 months of age (from the day the infant
becomes 6 months of age until the day before the infant achieves 8 months of age) at
the time of the first vaccination.
- Healthy subjects as established by medical history and clinical examination before
entering into the study.
- Born full-term with a minimum birth weight of 2.5 kilograms (kg).
- Subjects' parent(s)/LAR(s) need to have access to a consistent mean of telephone
contact or computer.
Query!
Minimum age
6
Months
Query!
Query!
Maximum age
7
Months
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- Child in care
- Use of any investigational or non-registered product other than the study vaccine
during the period starting 30 days before the first dose of study vaccine (Day -29 to
Day 1), or planned use during the study period.
- Chronic administration of immunosuppressants or other immune-modifying drugs during
the period starting six months prior to the first vaccine. For corticosteroids, this
will mean prednisone = 0.5 milligrams (mg)/kg/day (for pediatric subjects), or
equivalent. Topical steroids are allowed.
- Administration of long-acting immune-modifying drugs or planned administration at any
time during the study period.
- Administration of immunoglobulins and/or any blood products during the period starting
three months before the first dose of study vaccine or planned administration during
the study period.
- Planned administration/administration of a vaccine not foreseen by the study protocol
in the period starting 30 days before the first dose and ending 30 days after the last
dose of vaccine administration, with the exception of scheduled routine pediatric
vaccines. Scheduled routine pediatric vaccines may be administered = 7 days before a
dose of study vaccine or = 7 days following a dose of study vaccine, with the
exception of live viral vaccines which may be administered = 14 days before a dose or
= 7 days after a dose.
- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
functional abnormality, as determined by physical examination or laboratory screening
tests.
- A history of, or on-going confirmed RSV disease or highly compatible clinical picture.
- Serious chronic illness.
- Major congenital defects.
- History of any neurological disorders or seizures.
- History of or current autoimmune disease.
- History of recurrent wheezing in the subject's lifetime.
- History of chronic cough.
- Previous hospitalization for lower respiratory illnesses.
- Previous, current or planned administration of Synagis (palivizumab).
- Neurological complications following any prior vaccination.
- Born to a mother known or suspected to be Human Immunodeficiency Virus (HIV)-positive
.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
medical history and physical examination .
- Family history of congenital or hereditary immunodeficiency.
- Previous vaccination with a recombinant simian or human adenoviral vaccine.
- History of any reaction or hypersensitivity to any component of the vaccines
(investigational or control) or placebo used in this study or any contraindication to
them.
- Hypersensitivity to latex.
- Current severe eczema.
- Acute disease and/or fever at the time of enrolment (Visit 1).
- Any clinically significant Grade 1 or any = Grade 2 hematological or biochemical
laboratory abnormality detected at the last screening blood sampling.
- Any medical condition that in the judgment of the investigator would make
intramuscular (IM) injection unsafe.
- Any other conditions that the investigator judges may interfere with study procedures,
findings.
- Any conditions that could constitute a risk for the subjects while participating to
this study.
- Weight below the fifth percentile of the local weight-for-age curve according to the
World Health Organization (WHO) weight- for- age tables. Participating in another
clinical study, at any time during the study period, in which the subject or mother
(if breastfeeding) has been or will be exposed to an investigational or a
non-investigational vaccine/product.
- Planned move to a location that will prohibit participating in the trial until study
end.
- For Thailand only, subjects who have received Synflorix prior to enrolment.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/04/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
22/07/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
201
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Georgia
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Idaho
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Kentucky
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Maryland
Query!
Country [5]
0
0
Brazil
Query!
State/province [5]
0
0
Minas Gerais
Query!
Country [6]
0
0
Brazil
Query!
State/province [6]
0
0
São Paulo
Query!
Country [7]
0
0
Canada
Query!
State/province [7]
0
0
Nova Scotia
Query!
Country [8]
0
0
Canada
Query!
State/province [8]
0
0
Quebec
Query!
Country [9]
0
0
Canada
Query!
State/province [9]
0
0
Québec
Query!
Country [10]
0
0
Colombia
Query!
State/province [10]
0
0
Cali
Query!
Country [11]
0
0
Finland
Query!
State/province [11]
0
0
Jarvenpaa
Query!
Country [12]
0
0
Finland
Query!
State/province [12]
0
0
Tampere
Query!
Country [13]
0
0
Finland
Query!
State/province [13]
0
0
Turku
Query!
Country [14]
0
0
Italy
Query!
State/province [14]
0
0
Lazio
Query!
Country [15]
0
0
Mexico
Query!
State/province [15]
0
0
Mexico
Query!
Country [16]
0
0
Panama
Query!
State/province [16]
0
0
Chiriquí
Query!
Country [17]
0
0
Panama
Query!
State/province [17]
0
0
Panama
Query!
Country [18]
0
0
Poland
Query!
State/province [18]
0
0
Debica
Query!
Country [19]
0
0
Poland
Query!
State/province [19]
0
0
Gdansk
Query!
Country [20]
0
0
Poland
Query!
State/province [20]
0
0
Trzebnica
Query!
Country [21]
0
0
Poland
Query!
State/province [21]
0
0
Warszawa
Query!
Country [22]
0
0
Poland
Query!
State/province [22]
0
0
Wroclaw
Query!
Country [23]
0
0
Spain
Query!
State/province [23]
0
0
Burgos
Query!
Country [24]
0
0
Spain
Query!
State/province [24]
0
0
Madrid
Query!
Country [25]
0
0
Spain
Query!
State/province [25]
0
0
Majadahonda (Madrid)
Query!
Country [26]
0
0
Spain
Query!
State/province [26]
0
0
Santiago de Compostela
Query!
Country [27]
0
0
Spain
Query!
State/province [27]
0
0
Sevilla
Query!
Country [28]
0
0
Spain
Query!
State/province [28]
0
0
Valencia
Query!
Country [29]
0
0
Thailand
Query!
State/province [29]
0
0
Bangkok
Query!
Country [30]
0
0
Turkey
Query!
State/province [30]
0
0
Eskisehir
Query!
Country [31]
0
0
Turkey
Query!
State/province [31]
0
0
Izmir
Query!
Country [32]
0
0
Turkey
Query!
State/province [32]
0
0
Kayseri
Query!
Country [33]
0
0
United Kingdom
Query!
State/province [33]
0
0
Manchester
Query!
Country [34]
0
0
United Kingdom
Query!
State/province [34]
0
0
Southampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to provide critical information on the safety, reactogenicity
and immunogenicity profile of the investigational recombinant chimpanzee adenovirus Type
155-vectored RSV (ChAd155-RSV) vaccine in infants likely to be unexposed to RSV and will
assess a single lower dose and a higher two dose regimen, before moving to future studies.
This study will also assess if there is a risk of 'vaccine-induced enhanced RSV disease'
after vaccination of these infants with the ChAd155-RSV vaccine.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03636906
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03636906
Download to PDF